Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crovalimab for prevention of vaso-occlusive episodes in sickle cell disease
NL-OMON53710Phase 2Not yet recruiting
- Sponsor
- Roche
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of crovalimab in sickle cell disease (SCD), sponsored by Roche. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
crovalimab
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NL-OMON53710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53710.